Wegovy Cuts Food Obsession, Boosts Well-being: Novo Nordisk

Dagens Industri reports that Danish pharmaceutical company Novo Nordisk has released new findings from an American study, "Inform," detailing the effects of its obesity medication, Wegovy. Presented in conjunction with the EASD diabetes conference, the study's primary conclusion indicates that Wegovy significantly reduces "food noise," defined as a compulsive preoccupation with food. This reduction leads to a substantial decrease in obsessive food-related thoughts among users. Beyond appetite control, the research highlighted broader benefits, revealing considerable improvements in the mental well-being of participants taking Wegovy. Additionally, the study observed that individuals using the medication adopted healthier habits. Novo Nordisk initially shared these findings through a company press release. Nyhetsbyrån Direkt reported that this information was disseminated via Novo Nordisk's press release. However, the source material did not provide specific details regarding the study's methodology or metrics.